Unknown

Dataset Information

0

Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.


ABSTRACT:

Background

Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China's healthcare system perspective.

Methods

A combination of the decision tree and Markov model was constructed to evaluate the cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase in the treatment of acute ischemic stroke over a lifetime horizon. Efficacy data were derived from pivotal clinical trials of edaravone dexborneol and human urinary kallidinogenase (TASTE trial and RESK trial, respectively) and adjusted using matching-adjusted indirect comparison. Cost and health utility inputs were extracted from published literature and open databases. One-way deterministic sensitivity and probabilistic sensitivity analyses were performed to examine the robustness of the results.

Results

Compared with human urinary kallidinogenase, edaravone dexborneol generated 0.153 incremental quality-adjusted life years (QALYs) with an incremental cost of ¥856, yielding an incremental cost-effectiveness ratio of ¥5,608 per QALY gained under the willingness-to-pay threshold (one-time gross domestic product per capita). Both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis demonstrated the robustness of the base case results.

Conclusions

Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.

SUBMITTER: Chen P 

PROVIDER: S-EPMC10823610 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.

Chen Pingyu P   Luo Mengjie M   Chen Yanqiu Y   Zhang Yanlei Y   Wang Chao C   Li Hongchao H  

Health economics review 20240129 1


<h4>Background</h4>Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China's healthcare system perspective.<h4>Methods</h4>A combination of the decision tree and Markov model was constructed to evaluate the cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase in the treatment of acut  ...[more]

Similar Datasets

| S-EPMC9622952 | biostudies-literature
| S-EPMC10860239 | biostudies-literature
| S-EPMC11418712 | biostudies-literature
| S-EPMC11894225 | biostudies-literature
| S-EPMC10877503 | biostudies-literature
| S-EPMC9410976 | biostudies-literature
| S-EPMC7780570 | biostudies-literature
| S-EPMC10472948 | biostudies-literature
| S-EPMC5561313 | biostudies-other
| S-EPMC8611767 | biostudies-literature